Wall Street brokerages expect Hill-Rom Holdings, Inc. (NYSE:HRC) to post earnings of $1.02 per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Hill-Rom’s earnings, with the lowest EPS estimate coming in at $1.01 and the highest estimate coming in at $1.02. Hill-Rom reported earnings of $0.88 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 15.9%. The firm is scheduled to report its next earnings results on Friday, April 27th.
According to Zacks, analysts expect that Hill-Rom will report full year earnings of $4.62 per share for the current year, with EPS estimates ranging from $4.60 to $4.63. For the next financial year, analysts anticipate that the business will report earnings of $5.13 per share, with EPS estimates ranging from $5.08 to $5.19. Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Hill-Rom.
Hill-Rom (NYSE:HRC) last posted its quarterly earnings results on Friday, January 26th. The medical technology company reported $0.92 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.79 by $0.13. Hill-Rom had a net margin of 7.14% and a return on equity of 20.24%. The firm had revenue of $669.70 million for the quarter, compared to analyst estimates of $670.00 million. During the same quarter last year, the firm posted $0.75 earnings per share. Hill-Rom’s revenue for the quarter was up 5.1% compared to the same quarter last year.
Shares of Hill-Rom (NYSE HRC) traded down $0.96 during trading hours on Thursday, reaching $82.44. 858,663 shares of the company’s stock traded hands, compared to its average volume of 663,351. The company has a debt-to-equity ratio of 1.39, a current ratio of 1.75 and a quick ratio of 1.29. Hill-Rom has a one year low of $59.96 and a one year high of $91.11. The firm has a market capitalization of $5,380.00, a P/E ratio of 27.95, a price-to-earnings-growth ratio of 1.45 and a beta of 1.05.
In other news, CEO John J. Greisch sold 125,241 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $82.59, for a total transaction of $10,343,654.19. Following the completion of the sale, the chief executive officer now owns 280,851 shares of the company’s stock, valued at $23,195,484.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Paul Sherwood Johnson sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $82.99, for a total transaction of $82,990.00. Following the sale, the senior vice president now directly owns 1,066 shares of the company’s stock, valued at approximately $88,467.34. The disclosure for this sale can be found here. Insiders have sold 226,241 shares of company stock valued at $18,708,644 in the last three months. Corporate insiders own 1.90% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in HRC. Citigroup Inc. grew its position in shares of Hill-Rom by 21.1% during the second quarter. Citigroup Inc. now owns 2,483 shares of the medical technology company’s stock worth $198,000 after buying an additional 433 shares in the last quarter. DekaBank Deutsche Girozentrale grew its position in shares of Hill-Rom by 101.0% during the third quarter. DekaBank Deutsche Girozentrale now owns 2,720 shares of the medical technology company’s stock worth $204,000 after buying an additional 1,367 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Hill-Rom during the third quarter worth approximately $207,000. CAPROCK Group Inc. acquired a new stake in shares of Hill-Rom during the fourth quarter worth approximately $211,000. Finally, Braun Stacey Associates Inc. acquired a new position in Hill-Rom in the fourth quarter worth $233,000. 81.34% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.thecerbatgem.com/2018/02/06/1884238.html.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.